3 results
To characterize the exposure-response relationship of MVT-602 effects on luteinizing hormone (LH) concentrations after subcutaneous administration of single 0.1 to 3 µg doses of MVT-602 or placebo in healthy premenopausal women undergoing COS to…
The objective of this study is to gather more information to find out if one of these rituximab administration methods is more effective and safer in the treatment of DLBCL patients. This study will also collect information on patient satisfaction…
See protocol page 9This study designed to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor (ICM) or newer approved version, the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for…